EA201991387A1 - ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ - Google Patents
ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙInfo
- Publication number
- EA201991387A1 EA201991387A1 EA201991387A EA201991387A EA201991387A1 EA 201991387 A1 EA201991387 A1 EA 201991387A1 EA 201991387 A EA201991387 A EA 201991387A EA 201991387 A EA201991387 A EA 201991387A EA 201991387 A1 EA201991387 A1 EA 201991387A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tricyclic
- jones
- applications
- pyrimidine derivatives
- compounds
- Prior art date
Links
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 title 1
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
В документе раскрыты соединения формула также их аналоги, переменные которых определены в данном документе. Также предоставлены их фармацевтические композиции. В некоторых аспектах соединения и композиции, представленные в настоящем документе, могут быть использованы для ингибирования RORγ и/или снижения экспрессии IL-17. Также предоставлены способы введения предложенных в данном документе соединений и композиций пациенту, нуждающемуся в этом, например, для лечения или профилактики заболеваний или расстройств, связанных с воспалительными или аутоиммунными расстройствами.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662435588P | 2016-12-16 | 2016-12-16 | |
PCT/US2017/000094 WO2018111315A1 (en) | 2016-12-16 | 2017-12-16 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991387A1 true EA201991387A1 (ru) | 2019-12-30 |
Family
ID=61028153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991387A EA201991387A1 (ru) | 2016-12-16 | 2017-12-16 | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ |
Country Status (20)
Country | Link |
---|---|
US (2) | US11292781B2 (ru) |
EP (1) | EP3555062A1 (ru) |
JP (1) | JP7177059B2 (ru) |
KR (2) | KR20190110089A (ru) |
CN (1) | CN110248932B (ru) |
AU (1) | AU2017377852B2 (ru) |
BR (1) | BR112019012271A2 (ru) |
CA (2) | CA3046183C (ru) |
CL (1) | CL2019001658A1 (ru) |
CO (1) | CO2019007409A2 (ru) |
EA (1) | EA201991387A1 (ru) |
IL (1) | IL267274B2 (ru) |
MX (1) | MX2019007088A (ru) |
NZ (1) | NZ754764A (ru) |
PE (1) | PE20191490A1 (ru) |
PH (1) | PH12019501371A1 (ru) |
TW (1) | TWI831738B (ru) |
UA (1) | UA127376C2 (ru) |
WO (1) | WO2018111315A1 (ru) |
ZA (1) | ZA201904227B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2276493T3 (pl) | 2008-04-18 | 2019-05-31 | Reata Pharmaceuticals Inc | Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17 |
ES2861393T3 (es) | 2012-04-27 | 2021-10-06 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones |
MX2019004685A (es) | 2016-10-24 | 2019-08-21 | Astrazeneca Ab | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer. |
MX2019008438A (es) | 2017-01-30 | 2019-10-30 | Astrazeneca Ab | Moduladores del receptor de estrogeno. |
MX2020007956A (es) | 2018-01-29 | 2021-01-08 | Capulus Therapeutics Llc | Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros. |
US20210147380A1 (en) * | 2018-06-20 | 2021-05-20 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
TWI829001B (zh) * | 2020-08-07 | 2024-01-11 | 日商大鵬藥品工業股份有限公司 | 新穎環烯酮化合物或其鹽 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
EP1142889A1 (en) | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
JP2005507892A (ja) | 2001-09-19 | 2005-03-24 | ファルマシア・コーポレーション | 炎症の治療のための置換されたピラゾリルベンゼンスルファミド化合物 |
AU2003235676A1 (en) | 2002-01-15 | 2003-07-30 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
AU2003303128A1 (en) | 2002-05-13 | 2004-08-13 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
WO2006089406A1 (en) | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
EP2094651A1 (en) | 2006-11-17 | 2009-09-02 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
WO2008064132A2 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
WO2009089545A1 (en) | 2008-01-11 | 2009-07-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
PL2276493T3 (pl) | 2008-04-18 | 2019-05-31 | Reata Pharmaceuticals Inc | Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17 |
BRPI0911105B1 (pt) | 2008-04-18 | 2022-11-08 | Reata Pharmaceuticals, Inc | Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos |
EA022588B1 (ru) | 2008-04-18 | 2016-01-29 | Ритэ Фамэсутикл, Инк. | Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце |
WO2009134726A1 (en) | 2008-04-28 | 2009-11-05 | Abbott Laboratories | Substituted pyrimidine derivatives as histamine h4 receptor ligands |
CA2731650A1 (en) | 2008-07-22 | 2010-01-28 | Tadashi Honda | Monocyclic cyanoenones and methods of use thereof |
US8778990B2 (en) | 2008-11-04 | 2014-07-15 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
TR201909743T4 (tr) | 2009-02-13 | 2019-07-22 | Reata Pharmaceuticals Inc | Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri. |
CA2795320C (en) | 2010-04-12 | 2019-01-22 | Reata Pharmaceuticals, Inc. | Method of treating obesity using antioxidant inflammation modulators |
TWI527788B (zh) * | 2010-12-17 | 2016-04-01 | 瑞塔醫藥有限責任公司 | 作為抗氧化發炎調節劑之吡唑及嘧啶三環烯酮 |
UY33946A (es) | 2011-03-11 | 2012-08-31 | Reata Pharmaceuticals Inc | Derivados de c4-monometil triterpenoides y sus métodos de uso |
ES2861393T3 (es) | 2012-04-27 | 2021-10-06 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones |
WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
PL2892912T3 (pl) | 2012-09-10 | 2019-10-31 | Reata Pharmaceuticals Inc | C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
CN104768965B (zh) | 2012-09-10 | 2018-05-11 | 里亚塔医药公司 | 齐墩果酸的c17-杂芳基衍生物和其使用方法 |
JP6564372B2 (ja) | 2013-08-23 | 2019-08-21 | リアタ ファーマシューティカルズ インコーポレイテッド | バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 |
WO2015112792A1 (en) | 2014-01-24 | 2015-07-30 | Abbvie Inc. | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
CA2953306C (en) * | 2014-06-25 | 2023-10-31 | Piramal Enterprises Limited | Fused triterpene compounds and uses thereof |
WO2016084790A1 (ja) * | 2014-11-25 | 2016-06-02 | 第一三共株式会社 | ヒドロナフトキノリン誘導体 |
EA038328B1 (ru) | 2015-02-12 | 2021-08-10 | Рита Фармасьютикалз, Инк. | Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления |
MX2019004685A (es) | 2016-10-24 | 2019-08-21 | Astrazeneca Ab | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer. |
PT3555064T (pt) | 2016-12-16 | 2023-01-20 | Pfizer | Agonistas dos receptores glp-1 e suas utilizações |
PE20191322A1 (es) | 2016-12-16 | 2019-09-24 | Basf Se | Compuestos plaguicidas |
AU2017377069B2 (en) | 2016-12-16 | 2020-07-23 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the JAK family of kinases |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
CN112654610A (zh) | 2018-06-15 | 2021-04-13 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
US20210147380A1 (en) | 2018-06-20 | 2021-05-20 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
-
2017
- 2017-12-15 TW TW106144248A patent/TWI831738B/zh active
- 2017-12-16 BR BR112019012271A patent/BR112019012271A2/pt active Search and Examination
- 2017-12-16 KR KR1020197018696A patent/KR20190110089A/ko not_active IP Right Cessation
- 2017-12-16 US US16/468,054 patent/US11292781B2/en active Active
- 2017-12-16 EP EP17835730.7A patent/EP3555062A1/en active Pending
- 2017-12-16 EA EA201991387A patent/EA201991387A1/ru unknown
- 2017-12-16 UA UAA201908085A patent/UA127376C2/uk unknown
- 2017-12-16 AU AU2017377852A patent/AU2017377852B2/en active Active
- 2017-12-16 PE PE2019001274A patent/PE20191490A1/es unknown
- 2017-12-16 WO PCT/US2017/000094 patent/WO2018111315A1/en unknown
- 2017-12-16 CN CN201780085431.4A patent/CN110248932B/zh active Active
- 2017-12-16 KR KR1020247003600A patent/KR20240019389A/ko not_active Application Discontinuation
- 2017-12-16 JP JP2019531921A patent/JP7177059B2/ja active Active
- 2017-12-16 MX MX2019007088A patent/MX2019007088A/es unknown
- 2017-12-16 IL IL267274A patent/IL267274B2/en unknown
- 2017-12-16 CA CA3046183A patent/CA3046183C/en active Active
- 2017-12-16 CA CA3223645A patent/CA3223645A1/en active Pending
- 2017-12-16 NZ NZ754764A patent/NZ754764A/en unknown
-
2019
- 2019-06-14 CL CL2019001658A patent/CL2019001658A1/es unknown
- 2019-06-14 PH PH12019501371A patent/PH12019501371A1/en unknown
- 2019-06-27 ZA ZA2019/04227A patent/ZA201904227B/en unknown
- 2019-07-10 CO CONC2019/0007409A patent/CO2019007409A2/es unknown
-
2022
- 2022-01-18 US US17/577,456 patent/US20220135534A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201835051A (zh) | 2018-10-01 |
US20200131148A1 (en) | 2020-04-30 |
EP3555062A1 (en) | 2019-10-23 |
CA3046183C (en) | 2024-02-20 |
IL267274B2 (en) | 2024-03-01 |
CL2019001658A1 (es) | 2019-09-27 |
AU2017377852B2 (en) | 2022-02-17 |
KR20190110089A (ko) | 2019-09-27 |
AU2017377852A1 (en) | 2019-07-11 |
NZ754764A (en) | 2023-04-28 |
CA3046183A1 (en) | 2018-06-21 |
WO2018111315A1 (en) | 2018-06-21 |
CO2019007409A2 (es) | 2019-07-31 |
JP2020512289A (ja) | 2020-04-23 |
IL267274A (en) | 2019-08-29 |
US11292781B2 (en) | 2022-04-05 |
WO2018111315A8 (en) | 2019-07-11 |
US20220135534A1 (en) | 2022-05-05 |
MX2019007088A (es) | 2019-10-15 |
CA3223645A1 (en) | 2018-06-21 |
JP7177059B2 (ja) | 2022-11-22 |
CN110248932A (zh) | 2019-09-17 |
PH12019501371A1 (en) | 2019-10-28 |
BR112019012271A2 (pt) | 2019-12-03 |
PE20191490A1 (es) | 2019-10-21 |
CN110248932B (zh) | 2023-03-10 |
KR20240019389A (ko) | 2024-02-14 |
TWI831738B (zh) | 2024-02-11 |
ZA201904227B (en) | 2024-02-28 |
UA127376C2 (uk) | 2023-08-02 |
IL267274B1 (en) | 2023-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
PH12020500500A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
EA201890767A1 (ru) | C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений | |
EA201790528A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
EA201790088A1 (ru) | Ингибиторы syk | |
EA201790442A1 (ru) | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae | |
EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
MD3359146T2 (ro) | Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
EA201991951A1 (ru) | Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
MX2019012522A (es) | Compuestos y metodos terapeuticos. | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. | |
EA202092446A1 (ru) | ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34 | |
MX2016008968A (es) | Compuestos organicos. |